Cannabis and cannabis-derived substances are worldwide the most frequently consumed psychopharmaceuticals [1]. Over the past decade, attitudes toward the recreational and medicinal use of cannabis have rapidly evolved from illicit to decriminalized to legalized at the state level. By 2025, legal cannabis sales are projected to generate $23 billion in the United States [2]. Delta 9-tetrahydrocannabinol (THC) is a well described psychoactive constituent which interacts with the cannabinoid receptor type 1 (CB1) and the complex network of neurologic transmitters to induce psychopharmacological effects [3].
